Current and completed investments

Synartro is developing a unique treatment for knee osteoarthritis by combining two proven drugs, which will offer an effective and safe alternative to today’s treatments.

PharmNovo develops drugs for chronic pain based on a new type of selective delta opioids. The main candidate PN6047 shows promising results on effective pain relief without negative side effects.

Osteoarthritis affects more than 240 million people globally. Synartro is developing a novel therapy for knee osteoarthritis with fewer side effects and improved efficacy to meet the needs of the ageing population.

Cavis Technologies has developed a combined guidewire/catheter, Wirecath®, for diagnosis of people with coronary heart disease. Wirecath® is expected to provide important clinical benefits.